Managing adverse events in kidney cancer patients on immunotherapy/TKI combination treatment

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center, Texas in the USA talks about managing adverse events to immunotherapy and targeted therapy combinations. There are more adverse events from any type of combination treatment compared to single treatments, especially immune adverse events. Nivolumab alone is very well tolerated and quite easy […]

read more

Managing immune-related adverse events

In these video interviews, Dr Eric Jonasch from MD Anderson Cancer Center in Texas and Dr Monty Pal from the City of Hope Hospital in California talk about immune-related adverse events in people with advanced kidney cancer taking combination therapies and immunotherapy: Managing Adverse Events Among RCC Patients Receiving Combination Treatment With Targeted Therapy and […]

read more

Checkpoint inhibitor re-challenge after immune-related adverse events

Immunotherapy has revolutionised treatment in many cancers, including renal cell carcinoma (RCC). This study looked at giving patients immunotherapy after they had experienced an immune-related adverse event. With nivolumab in RCC, the probability of having a severe or life-threatening adverse event is very low. Nivolumab alone is very well tolerated. However, with the ipilimumab plus […]

read more

Nephritis as a potential predictor of response to immune checkpoint inhibitors in kidney cancer

This study, to be published in Journal for Immunotherapy of Cancer, looks at the immune-related adverse event, acute interstitial nephritis (inflammation of the kidney tissues), as a biomarker for response to immune checkpoint inhibitors. Using a database, the researchers identified 177 patients with metastatic renal cell carcinoma (RCC) who received at least one dose of […]

read more

γ-Glutamyltransferase as a biomarker in patients on nivolumab for metastatic kidney cacner

A protein called γ-glutamyltransferase can predict survival in patients with local and metastatic renal cell carcinoma (RCC); however, in patients treated with immune checkpoint inhibitors, such as nivolumab, this predictive role is unknown. A study to be published in the International Journal of Clinical Oncology aimed to investigate the role of γ-glutamyltransferase as a predictive […]

read more

PDIGREE trial: Ipilimumab plus nivolumab with cabozantinib for untreated advanced kidney cancer

During this video interview from UroToday, Dr Tian Zhang from the Duke Cancer Centre in North Carolina, USA talks about the PDIGREE trial and the effect of the COVID-19 pandemic on the trial. PDIGREE is a novel adaptive study which will help answer many important questions, such as treatment duration, when to use vascular endothelial […]

read more

New survival data for pembrolizumab plus axitinib in advanced kidney cancer

A paper published in The Lancet Oncology this month provides further follow-up data from the KEYNOTE-426 study, which shows superior efficacy of pembrolizumab plus axitinib over sunitinib in patients with untreated advanced renal cell carcinoma (RCC). Eight hundred and sixty one (861) patients were randomly assigned to receive pembrolizumab plus axitinib (432) or sunitinib (429). […]

read more

Safety and efficacy of tivozanib–nivolumab combination in patients with metastatic kidney cancer

In this phase 1b/2 study the researchers looked at a combination of tivozanib and nivolumab in 25 patients with metastatic renal cell carcinoma (RCC). Tivozanib is a targeted therapy called a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) that blocks the growth of blood vessels to the tumour, while nivolumab is an immune […]

read more

Immune-related adverse events from cabozantinib plus atezolizumab as first-line treatment for advanced kidney cancer

The COSMIC-021 clinical trial investigated a combination of cabozantinib and atezolizumab in untreated clear-cell renal cell carcinoma (RCC). In this video interview, Dr Monty Pal from the City of Hope Hospital in California discusses the side effects from this combination of drugs. There were two groups of patients; one on 60 mg of cabozantinib plus […]

read more
Showing 1 to 10 of 262 results
  TOP